ID | 1350 |
Name of the vaccine | Eupenta Inj. |
Microbe | Bacteria |
Disease name | Haemophilus influenzae type b (Hib) |
Name of bacteria | Haemophilus influenzae |
Type of vaccine | Conjugate |
Nucleic acid content | DNA |
Age | 6 to 8 weeks |
Description of the vaccine | Fully liquid pentavalent vaccine. |
Name of the manufacturer | LG Chem |
Name of the manufacturing country | NA |
Year of manufacture | 2020 |
Clinical Phase status | Clinical - Phase 4 |
Bacterial strain | Anaerobic gram-negative coccobacillus. |
Efficacy | NA |
Vaccine formulation | Liquid |
Dosage | Three doses of 0.5 mL at 6, 10 and 14 weeks. |
Mechanism of action | NA |
Route of administration | NA |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | For pertussis, tetanus, hepatitis B and diphtheria. |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Combination (3 doses) |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT04056728 |
Reference | NA |
Other name | NA |
Additional Links | NA
|